Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Sees Large Growth in Short Interest

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) saw a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 17,500 shares, an increase of 3,400.0% from the February 13th total of 500 shares. Based on an average daily trading volume, of 318,700 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the shares of the company are short sold.

Provectus Biopharmaceuticals Price Performance

Shares of OTCMKTS PVCT traded up $0.01 during trading hours on Wednesday, reaching $0.11. 449,379 shares of the stock were exchanged, compared to its average volume of 193,219. The stock’s fifty day simple moving average is $0.11 and its 200 day simple moving average is $0.11. Provectus Biopharmaceuticals has a 52 week low of $0.04 and a 52 week high of $0.22.

Provectus Biopharmaceuticals Company Profile

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.